- Home
- IEP vs PTCT Comparison
IEP vs PTCT Comparison
Compare IEP & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IEP
- PTCT
- Stock Information
- Founded
- IEP 1987
- PTCT 1998
- Country
- IEP United States
- PTCT United States
- Employees
- IEP N/A
- PTCT N/A
- Industry
- IEP Auto Parts:O.E.M.
- PTCT Biotechnology: Pharmaceutical Preparations
- Sector
- IEP Consumer Discretionary
- PTCT Health Care
- Exchange
- IEP Nasdaq
- PTCT Nasdaq
- Market Cap
- IEP 4.7B
- PTCT 5.3B
- IPO Year
- IEP 1987
- PTCT 2013
- Fundamental
- Price
- IEP $8.15
- PTCT $68.51
- Analyst Decision
- IEP
- PTCT Buy
- Analyst Count
- IEP 0
- PTCT 14
- Target Price
- IEP N/A
- PTCT $67.00
- AVG Volume (30 Days)
- IEP 605.9K
- PTCT 1.2M
- Earning Date
- IEP 11-07-2025
- PTCT 11-06-2025
- Dividend Yield
- IEP 24.55%
- PTCT N/A
- EPS Growth
- IEP N/A
- PTCT N/A
- EPS
- IEP N/A
- PTCT 7.72
- Revenue
- IEP $9,533,000,000.00
- PTCT $1,764,929,000.00
- Revenue This Year
- IEP N/A
- PTCT $120.26
- Revenue Next Year
- IEP $0.69
- PTCT N/A
- P/E Ratio
- IEP N/A
- PTCT $8.89
- Revenue Growth
- IEP N/A
- PTCT 96.00
- 52 Week Low
- IEP $7.27
- PTCT $35.51
- 52 Week High
- IEP $15.65
- PTCT $69.26
- Technical
- Relative Strength Index (RSI)
- IEP 39.78
- PTCT 72.99
- Support Level
- IEP $8.10
- PTCT $64.35
- Resistance Level
- IEP $8.24
- PTCT $67.24
- Average True Range (ATR)
- IEP 0.14
- PTCT 2.18
- MACD
- IEP 0.00
- PTCT 0.15
- Stochastic Oscillator
- IEP 11.54
- PTCT 93.46
About IEP Icahn Enterprises L.P.
Icahn Enterprises LP provides diversified business services in the United States. The company operates its business through varied segments which include Investment, Automotive, Energy, Food Packaging, Real Estate, Pharma, and Home Fashion. Among these, the Energy segment derives the maximum revenue from the company. Geographically, it generates maximum revenue from the United States.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.